Cytos Biotechnology AG

EQS-Adhoc: Cytos Biotechnology AG: bond conversion into equity effective

EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Bond
Cytos Biotechnology AG: bond conversion into equity effective

08.05.2015 / 15:46
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.


Cytos' bond conversion into equity effective

  - 77.49 million shares newly issued in exchange for convertible bonds

  - First day of trading of new shares originally scheduled for May 11,
2015 but due to mistake from SIS AG already possible on May 8, 2015

Schlieren (Zurich), Switzerland, May 8, 2015 - Cytos Biotechnology Ltd
("Cytos") today announced that the convertible bond restructuring has been
completed with effect as of May 8, 2015. As a result, 77'490'000 shares
have been issued on top of the 30'525'276 shares already issued and
outstanding. Hence, the total number of shares issued and outstanding now
amounts to 108'015'276 shares. All newly issued shares were originally
scheduled to be free for trading starting Monday, May 11, 2015 and are
equal to those already issued and listed at the SIX Swiss Exchange.
However, due to a mistake by SIS AG, certain shares were already possible
to trade on May 8, 2015 as per message below.

As announced previously, all claims from the convertible loan note holders
are eliminated upon the bonds conversion into equity. As a result, Cytos is
free of any debt going forward with immediate effect.

Message from SIS AG:


Switzerland: Friday, 8 May 2015: De-blocking of a shares Cytos
Biotechnology AG, Schlieren:

Due to a technical error the new shares of Cytos Biotechnology, ISIN
CH0011025217, resulting from the mandatory conversion 5.75 % Cytos
Biotechnology (ISIN CH0029060735) have been de-blocked already today around
9.00 CET, 8 May 2015 instead of 11 May 2015. Realizing the mistake the
decision was taken to keep the shares de-blocked.
We apologize for any inconvenience caused and thank you for your
Yours faithfully


For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
End of ad hoc announcement

Additional features:

Document title: Cytos_conversion_150508


08.05.2015 News transmitted by EQS Schweiz AG. - news

The issuer is responsible for the contents of the release.


Language:    English
Company:     Cytos Biotechnology AG
             Wagistr. 25
             8952 Schlieren
Phone:       +41 44 733 4747
Fax:         +41 44 733 4740
ISIN:        CH0011025217, CH0029060735
Valor:       -
Listed:      Regulated Unofficial Market in Berlin, Munich, Stuttgart;
             Open Market in Frankfurt ; SIX

End of News    EQS Group News-Service
355233 08.05.2015

Weitere Meldungen: Cytos Biotechnology AG

Das könnte Sie auch interessieren: